Based on its management philosophy of "Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy," the Takara Bio Group is developing businesses worldwide that support research and industry in the life sciences field while advancing the development of proprietary fundamental technologies.
We became a wholly-owned subsidiary of Takara Holdings Inc. in June 2026 following a tender offer for our shares by Takara Holdings Inc. in February 2026. This will enable us to collaborate closely with Takara Holdings Inc., and in the future, we intend to work together to create new businesses and improve the efficiency of our operations, which will lead to further growth.
The current business environment surrounding us continues to be challenging due to the worldwide sluggish in the life science research market. As a result of this situation, our earnings have deteriorated, and we are working on drastic structural reforms with an urgent need for rapid improvement.
In the field of the regenerative / cellular medicine and gene therapies, although the in-house clinical development project was discontinued, this is an area where further market expansion is expected, and we will continue our efforts as a supporting the industry. In addition, as shown in "Takara Bio Group Long-term Vision 2050," which expresses our ideal vision in 2050, we will expand the scope of our activities from traditional Human Health to Planetary Health. We are transforming ourselves into a structure that continuously generates earnings by capturing expanding needs, while contributing to the resolution of global social issues that can only be addressed by biotechnology.
It's time for us to transform ourselves into a future leap forward. We will take on the challenge of this transformation by mobilizing the strengths of every employee.
We look forward to your continued support in the future.
June 2026
Tsuyoshi Miyamura
President ＆ CEO
